TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00457977

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax (PPSV23)
Description: Injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar (PCV7)
Description: Injection
Study: NCT03354884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: cabozantinib 60 mg orally once daily
Study: NCT01485900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR407899A
Description: Pharmaceutical form:capsule~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR407899A
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT00394602

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview regarding perceptions of side effects that are related to chemoradiation treatment.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview regarding perceptions of side effects that are related to chemoradiation treatment.

Intervention type: OTHER
Intervention: Questionnaire
Description: 3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
Study: NCT01382121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Modeling
Description: Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: watching a video unrelated to the fitness test and self-efficacy
Study: NCT03551600

Intervention type: PROCEDURE
Intervention: Near-infrared spectroscopy (NIRS)
Description: NIRS analyzes regional oxygen saturations (rSO2)

Intervention type: PROCEDURE
Intervention: Near-infrared spectroscopy (NIRS)
Description: NIRS analyzes regional oxygen saturations (rSO2)

Intervention type: PROCEDURE
Intervention: Near-infrared spectroscopy (NIRS)
Description: NIRS analyzes regional oxygen saturations (rSO2)

Intervention type: PROCEDURE
Intervention: Near-infrared spectroscopy (NIRS)
Description: NIRS analyzes regional oxygen saturations (rSO2)
Study: NCT01719172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veriset™ Hemostatic Patch
Description: Topical Hemostat
Study: NCT03842605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Study: NCT02185794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxilaprevir
Description: Voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match voxilaprevir
Description: Placebo to match voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match voxilaprevir
Description: Placebo to match voxilaprevir tablets administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match voxilaprevir
Description: Placebo to match voxilaprevir tablets administered orally once daily
Study: NCT01900561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response Symptom Management
Description: The Interactive Voice Response (IVR) system will provide automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Newsletters
Description: Personally tailored newsletters will incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
Study: NCT00930163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab (MILR1444A)
Description: Subcutaneous repeating dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subcutaneous repeating dose
Study: NCT01510626

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food proteins
Description: Food proteins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Drug
Study: NCT00709488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talaporfin sodium
Description: LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of device in prostate urethra
Description: Placement of device in prostate urethra

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transurethral illumination with light emitting diodes (Litx™ BPH Device)
Description: Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
Study: NCT02826512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: niraparib 300 mg QD continuously
Study: NCT03021863

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group A Reminder
Description: Tone of reminder email (duty 14 days followed by duty 28 days for non-responders)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group B Reminder
Description: Tone of reminder email (encouragement 14 days followed by encouragement 28 days for non-responders)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group C Reminder
Description: Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group D Reminder
Description: Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group E Reminder
Description: Tone of reminder email (generic reminders 14 days followed by 28 days for non-responders)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group F Reminder
Description: Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group G Reminder
Description: Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group H Reminder
Description: Tone of reminder email ( duty14 days followed by generic for non-responders 28 days)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group I Reminder
Description: Tone of reminder email (encouragement 14 days followed by generic non-responders 28 days)
Study: NCT01667237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program
Description: The rehabilitation program will be a self-monitored and minimally supervised home-exercise program. Exercise training modalities and intensity will be adapted to patient's individual condition. It will include aerobic and strength exercises 5 times a week for 4 weeks. Aerobic training will be done on a portable ergocycle. The target intensity will correspond to 60% of the maximal work rate achieved during the maximal progressive cardio-pulmonary exercise test, aiming for a cumulative time of 40 minutes per day. The heart rate, corresponding to an exercise level of 60% of max exercise capacity during the maximum exercise test, will be noted and patients will be instructed to train at this heart rate ± 10 beats. Muscle exercises will be performed using elastic bands and use of gravity.
Study: NCT02901548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be given every 4 weeks at 1500 mg/kg IV for total of 12 months/13 doses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy with Biopsy
Description: Cystoscopy with biopsy and transurethral resection of the bladder tumor (TURBT) (if indicated) will be performed at baseline, month 3, 6, 9, 12, 18, and 24. The month 6 and 24 cystoscopy will be done in the operating room with mapping biopsy. Rest of the cystoscopic exam with biopsy will be performed in the out-patient office setting and if clinically indicated will be repeated in the operating room. Participants will be off study if any of the biopsies document muscle invasive (T2 or above) urothelial carcinoma. Participants will also be off study if their month 6, 9, 12, 18 biopsies show persistent (month 6) or recurrent CIS or invasive (T1 or above) urothelial carcinoma. Otherwise, participants will remain on study until after the month 24 mapping biopsy.
Study: NCT00879411

Intervention type: DRUG
Intervention: Micardis
Study: NCT04237935

Intervention type: DRUG
Intervention: Ticagrelor 90mg
Description: Ticagrelor 90 mg dispensing claim is used as the exposure group
Study: NCT02939898

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adjuvant therapy to recFSH during ovarian stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Adjuvant therapy to recFSH during ovarian stimulation
Study: NCT02902640

Intervention type: DRUG
Intervention: Guaifenesin
Description: Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
Study: NCT02132416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Will be used if tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID
Description: Will be used if tolerated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Initially intravenous administration and when tolerated oral slow-release pils will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioids
Description: Initially intravenous administration and when tolerated oral slow-release pils will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural anaesthesia
Description: Given by specialists in anaesthesiology and intensive care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural anaesthesia
Description: Given by specialists in anaesthesiology and intensive care.
Study: NCT00367744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Rosiglitazone 4mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rosiglitazone
Study: NCT03664674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTO-104
Description: Single intratympanic injection of 12 mg dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intratympanic injection of placebo
Study: NCT03494517

Intervention type: DRUG
Intervention: Magnesium Sulfate
Description: Baseline EEG measurement will be performed for 5 minutes before intravenous magnesium administration will start as defined by the administration scheme of the Women's Hospital of the Bern University Hospital. After completion of the bolus infusion and at the beginning of the maintenance infusion of magnesium the second EEG measure will be performed for another 5 minutes. After 4 hours of intravenous magnesium treatment the plasmatic magnesium concentration is expected to be at a steady-state. A third 5-minute measure will be performed at this time point.
Study: NCT04355533

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serology test
Description: volume according to child weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serology test
Description: volume according to child weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serology test
Description: volume according to child weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serology test
Description: volume according to child weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: serology test
Description: volume according to child weight

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swab
Description: nasopharyngeal swab for PCR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swab
Description: nasopharyngeal swab for PCR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swab
Description: nasopharyngeal swab for PCR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swab
Description: nasopharyngeal swab for PCR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nasopharyngeal swab
Description: nasopharyngeal swab for PCR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rectal swab
Description: rectal swab for PCR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rectal swab
Description: rectal swab for PCR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rectal swab
Description: rectal swab for PCR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rectal swab
Description: rectal swab for PCR

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: saliva sample
Description: for biocollection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: saliva sample
Description: for biocollection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: saliva sample
Description: for biocollection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: saliva sample
Description: for biocollection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: saliva sample
Description: for biocollection
Study: NCT04213144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magdent Cap MED
Description: Magdent is intended to be used for accelaration of soft tissue and bone healing

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MED
Description: Sham MED is intended to be used for soft tissue healing
Study: NCT02638207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NewGam
Description: In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NewGam
Description: In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NewGam
Description: In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
Study: NCT01025362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lactation counseling
Description: The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Child Health Services offered standard care
Study: NCT04297189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching and health information intervention
Description: 8 session intervention with,group meetings with coaching tools and health information on nutrition and physical activity and coping with stress.
Study: NCT04237935

Intervention type: DRUG
Intervention: Clopidogrel 75mg
Description: Clopidogrel 75 mg dispensing claim is used as the reference group
Study: NCT03629080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-101 vaccine
Description: HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-101 vaccine
Description: HB-101 is a bivalent vaccine that contains two replication deficient recombinant lymphocytic choriomeningitis virus (rLCMV) vectors expressing pp65 and a truncated isoform of gB of human CMV.
Study: NCT02185794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400 mg/100 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400 mg/100 mg FDC tablet administered orally once daily
Study: NCT02132416

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1g QID will be given to all patients unless allergies.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: 1g QID will be given to all patients unless allergies.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical management
Description: Fracture stabilization
Study: NCT00252499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: PPAR-gamma agonist, insulin sensitizer
Study: NCT01673594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SODAS MPH
Description: Adults with ADHD will receive open-label SODAS MPH
Study: NCT02902640

Intervention type: DRUG
Intervention: Sulfamethoxazole
Description: Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
Study: NCT01673594

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SODAS MPH
Description: Adults with ADHD will receive open-label SODAS MPH
Study: NCT02902640

Intervention type: DRUG
Intervention: Trimethoprim
Description: Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
Study: NCT01182545

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilation
Description: Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ventilation
Description: Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.
Study: NCT00765375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Neurotoxin Type A
Description: 1.5-3 units of Botox/lesion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacteriostatic saline
Description: .1 cc bacteriostatic saline/lesion
Study: NCT00237601

Intervention type: OTHER
Intervention: obstetric care

Intervention type: OTHER
Intervention: obstetric care
Study: NCT02601950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
Study: NCT01673594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Subjects randomized to the active double-blind group will receive Naltrexone HCl